A detailed history of Baker Tilly Wealth Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Baker Tilly Wealth Management, LLC holds 17,466 shares of GILD stock, worth $1.16 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
17,466
Previous 18,033 3.14%
Holding current value
$1.16 Million
Previous $1.46 Million 12.4%
% of portfolio
0.24%
Previous 0.24%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$71.58 - $87.29 $40,585 - $49,493
-567 Reduced 3.14%
17,466 $1.28 Million
Q4 2023

Jan 10, 2024

BUY
$73.27 - $83.09 $651,956 - $739,334
8,898 Added 97.41%
18,033 $1.46 Million
Q3 2023

Oct 10, 2023

BUY
$73.94 - $80.67 $254,427 - $277,585
3,441 Added 60.43%
9,135 $684,000
Q2 2023

Jul 20, 2023

BUY
$76.01 - $86.7 $9,729 - $11,097
128 Added 2.3%
5,694 $438,000
Q1 2023

Apr 12, 2023

BUY
$77.31 - $88.08 $11,596 - $13,212
150 Added 2.77%
5,566 $461,000
Q4 2022

Jan 26, 2023

SELL
$62.32 - $89.47 $135,546 - $194,597
-2,175 Reduced 28.65%
5,416 $0
Q3 2022

Oct 20, 2022

SELL
$59.54 - $68.01 $2,262 - $2,584
-38 Reduced 0.5%
7,591 $468,000
Q2 2022

Jul 28, 2022

BUY
$57.72 - $65.01 $12,005 - $13,522
208 Added 2.8%
7,629 $472,000
Q1 2022

Apr 27, 2022

SELL
$57.92 - $72.58 $53,054 - $66,483
-916 Reduced 10.99%
7,421 $441,000
Q4 2021

Feb 08, 2022

BUY
$64.88 - $73.64 $105,105 - $119,296
1,620 Added 24.12%
8,337 $605,000
Q3 2021

Nov 02, 2021

BUY
$67.69 - $73.03 $52,933 - $57,109
782 Added 13.18%
6,717 $469,000
Q2 2021

Jul 30, 2021

BUY
$63.47 - $69.35 $57,059 - $62,345
899 Added 17.85%
5,935 $409,000
Q1 2021

Apr 28, 2021

BUY
$60.0 - $68.46 $87,240 - $99,540
1,454 Added 40.59%
5,036 $325,000
Q4 2020

Feb 03, 2021

BUY
$56.65 - $64.55 $202,920 - $231,218
3,582 New
3,582 $209,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $83.5B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Baker Tilly Wealth Management, LLC Portfolio

Follow Baker Tilly Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Tilly Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baker Tilly Wealth Management, LLC with notifications on news.